ArticleBMC infectious diseases2020
Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical Experience of Ceftaroline Fosamil in Gram-Positive Infective Endocarditis: A Multicenter Real-World Observational Study.Antibiotics (Basel, Switzerland) · 2026Article
- Comparative effectiveness of adjunctive rifampicin versus gentamicin for prosthetic valve endocarditis due toJAC-antimicrobial resistance · 2025Article
- The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.Journal of clinical medicine · 2025Review
- Halogenated 3-Nitro-2Antibiotics (Basel, Switzerland) · 2025Article
- A Comparison of Mortality, Readmissions, and Outcomes in Injection Drug Use-Associated Infective Endocarditis Caused by Methicillin-Resistant Versus Methicillin-SusceptibleInfection and drug resistance · 2025Article
- Epidemiological differences, clinical aspects, and short-term prognosis of patients with healthcare-associated and community-acquired infective endocarditis.Infection prevention in practice · 2024Article
- Ceft-to-Ceft Study: Real-Life Experience with Ceftaroline and Ceftobiprole in Treatment of the Principal Infectious Syndromes in a Spanish Multicenter Hospital Cohort.Antibiotics (Basel, Switzerland) · 2023Article
- Two cases of refractory methicillin-susceptible staphylococcus aureus endocarditis responsive to ertapenem.Journal of geriatric cardiology : JGC · 2023Article
- Methicillin Resistance Increased the Risk of Treatment Failure in Native Joint Septic Arthritis Caused byAntibiotics (Basel, Switzerland) · 2023Article
- Article
- Epidemiologic and clinical characteristics of infective endocarditis: a single-center retrospective study in the Bronx, New York.Infection · 2022Article
- APTC-C-SA01: A Novel Bacteriophage Cocktail TargetingInternational journal of molecular sciences · 2022Article
- No Correlation between Biofilm-Forming Capacity and Antibiotic Resistance in EnvironmentalPathogens (Basel, Switzerland) · 2022Article
- Unreliability of Clinical Prediction Rules to Exclude without Echocardiography Infective Endocarditis inJournal of clinical medicine · 2022Article
- Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series.JAC-antimicrobial resistance · 2021Article
- [Evolution of antimicrobial resistance and mortality in Staphylococcus aureus endocarditis during 15 years in a university hospital].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Article
- Article
- Risk Factors, Screening, and Treatment Challenges inOpen forum infectious diseases · 2021Article
- Comparative effectiveness of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a systematic review of observational studies.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundS. aureus (SA) infective endocarditis (IE) has a very high mortality, attributed to the age and comorbidities of patients, inadequate or delayed antibiotic treatment, and methicillin resistance, among other causes. The main study objective was to analyze epidemiological and clinical differences between IE by methicillin-resistant versus methicillin-susceptible SA (MRSA vs. MSSA) and to examine prognostic factors for SA endocarditis, including methicillin resistance and vancomycin minimum inhibitory concentration (MIC) values > 1 μg/mL to MRSA.
methodsPatients with SA endocarditis were consecutively and prospectively recruited from the Andalusia endocarditis cohort between 1984 and January 2017.
resultsWe studied 437 patients with SA endocarditis, which was MRSA in 13.5% of cases. A greater likelihood of history of COPD (OR 3.19; 95% CI 1.41-7.23), invasive procedures, or recognized infection focus in the 3 months before IE onset (OR 2.9; 95% CI 1.14-7.65) and of diagnostic delay (OR 3.94; 95% CI 1.64-9.5) was observed in patients with MRSA versus MSSA endocarditis. The one-year mortality rate due to SA endocarditis was 44.3% and associated with decade of endocarditis onset (1985-1999) (OR 8.391; 95% CI (2.82-24.9); 2000-2009 (OR 6.4; 95% CI 2.92-14.06); active neoplasm (OR 6.63; 95% CI 1.7-25.5) and sepsis (OR 2.28; 95% CI 1.053-4.9). Methicillin resistance was not associated with higher IE-related mortality (49.7 vs. 43.1%; p = 0.32).
conclusionMRSA IE is associated with COPD, previous invasive procedure or recognized infection focus, and nosocomial or healthcare-related origin. Methicillin resistance does not appear to be a decisive prognostic factor for SA IE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.